Data | Time point | ||||
---|---|---|---|---|---|
Baseline | Visit 1 | Visit 2* | Visit 3i or Day 8c | Day 90 | |
Demographics, alcohol intake, smoking history, drug history, height, weight, serum creatinine, haematocrit | ✓ | ||||
Warfarin therapy details- indication, intended duration, target INR, newly commenced or continuing, heparin pre-treatment, inpatient doses/INRs, doses/INR on discharge, warfarin counselling documented | ✓ | ||||
Medications, warfarin drug interactions | ✓ | ✓ | ✓ | ||
Medical history | ✓ | ||||
INR | ✓ | ✓** | ✓** | ✓** | ✓ |
Warfarin dosing/INR history | ✓ | ✓ | ✓ | ||
Number of GP consultations (since discharge, or between Days 8 and 90) | ✓ | ✓ | |||
Adverse events, hospital readmissions | ✓ | ✓ | |||
Warfarin continuing, reason for discontinuation | ✓ | ✓ | ✓ | ✓ | |
Beyth Bleeding Risk score | ✓C | ✓I | |||
Warfarin dose, changes recommended, visit outcome, visit length, travel time | ✓ | ✓ | ✓ | ||
QoL (EQ-5D), warfarin knowledge | ✓ | ✓ | ✓ | ||
QoL (Duke Anticoagulation Satisfaction Scale (DASS)) | ✓ | ||||
Adherence (Tool for Adherence Behaviour Screening (TABS)) | ✓ | ✓ | |||
Self-reported health services utilisation | ✓ |